Trials / Completed
CompletedNCT04380597
Observational Study in Patients With Nail Psoriasis Treated With Enstilar® to Assess the Severity Change and the Quality of Life
Observational and Prospective Study in Patients With Nail Psoriasis Treated With Calcipotriene and Betamethasone Dipropionate Aerosol Foam to Evaluate the Change in the Severity of Psoriasis and in the Quality of Life
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 10 (actual)
- Sponsor
- Angeles Florez · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
Observational, prospective and multicentre study to evaluate the effectiveness of calcipotriene and betamethasone dipropionate aerosol foam (Cal / BD), prescribed according to clinical practice and following the Product Data Sheet instructions, in the topical treatment of nail psoriasis according to the change in the score of the Nail Psoriasis Severity Index (NAPSI) at 12 weeks of treatment with respect to the initial score.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Calcipotriene and betamethasone dipropionate aerosol foam | Prescribed according to clinical practice and following Product Data Sheet instructions |
Timeline
- Start date
- 2019-03-26
- Primary completion
- 2019-12-15
- Completion
- 2021-07-30
- First posted
- 2020-05-08
- Last updated
- 2021-08-02
Locations
1 site across 1 country: Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04380597. Inclusion in this directory is not an endorsement.